Royalty Pharma (NASDAQ:RPRX) Raised to Strong-Buy at TD Cowen

Royalty Pharma (NASDAQ:RPRX) was upgraded by stock analysts at TD Cowen to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Other equities research analysts have also issued research reports about the stock. Citigroup dropped their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, October 25th. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $41.67.

Royalty Pharma Stock Down 0.1 %

RPRX opened at $25.23 on Tuesday. Royalty Pharma has a 1 year low of $24.05 and a 1 year high of $31.66. The firm has a 50 day moving average price of $26.26 and a 200 day moving average price of $27.11. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54. The company has a market cap of $14.87 billion, a PE ratio of 13.07, a price-to-earnings-growth ratio of 4.36 and a beta of 0.46.

Institutional Trading of Royalty Pharma

Large investors have recently modified their holdings of the business. Franklin Resources Inc. boosted its holdings in Royalty Pharma by 5.0% in the third quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company’s stock valued at $40,705,000 after purchasing an additional 70,130 shares during the last quarter. Van ECK Associates Corp raised its position in shares of Royalty Pharma by 171.1% in the 3rd quarter. Van ECK Associates Corp now owns 101,500 shares of the biopharmaceutical company’s stock valued at $2,777,000 after purchasing an additional 64,057 shares in the last quarter. Summit Global Investments purchased a new position in shares of Royalty Pharma during the 3rd quarter valued at approximately $735,000. Two Sigma Advisers LP grew its position in shares of Royalty Pharma by 44.7% during the third quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock worth $85,809,000 after buying an additional 936,900 shares in the last quarter. Finally, New South Capital Management Inc. grew its position in shares of Royalty Pharma by 5.0% during the third quarter. New South Capital Management Inc. now owns 2,466,371 shares of the biopharmaceutical company’s stock worth $69,774,000 after buying an additional 117,394 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.